Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy
Life expectancy in patients with multiple myeloma is increasing because of the availability of
an increasing number of novel agents with various mechanisms of action against the …
an increasing number of novel agents with various mechanisms of action against the …
[HTML][HTML] In-hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell …
L Sanchez, M Sylvester, R Parrondo, V Mariotti… - Biology of Blood and …, 2017 - Elsevier
Autologous hematopoietic stem cell transplantation (auto-HSCT) has improved survival in
patients with multiple myeloma (MM) and is increasingly used in elderly patients. The aim of …
patients with multiple myeloma (MM) and is increasingly used in elderly patients. The aim of …
The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution
M Arun, D Brauneis, G Doros, AC Shelton… - Bone Marrow …, 2017 - nature.com
High-dose melphalan and autologous stem cell transplantation (HDM/SCT) can induce
hematologic responses and prolong survival in selected patients with Immunoglobulin light …
hematologic responses and prolong survival in selected patients with Immunoglobulin light …
A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma
A Dispenzieri, A D'Souza, MA Gertz… - Bone Marrow …, 2017 - nature.com
This phase 1 study (clinical trial NCT00477815) was conducted to determine the maximum
tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan (90 Y-Zevalin) with high dose …
tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan (90 Y-Zevalin) with high dose …
High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges
E Muchtar, H Magen, MA Gertz - Leukemia & Lymphoma, 2017 - Taylor & Francis
The term high-risk multiple myeloma is aimed to identify a heterogeneous group of patients
who are more likely to progress and die early of their disease. Therefore, recognition of …
who are more likely to progress and die early of their disease. Therefore, recognition of …
Gender-specific aspects in patients with multiple myeloma undergoing autologous stem cell transplantation: a single-center experience
D Posch, W Rabitsch, P Wohlfarth, M Leiner… - Oncology, 2017 - karger.com
Objective: Limited data exist on gender-specific aspects in hematologic malignancies and
have been obtained mostly in non-Hodgkin lymphomas. The objective of this study was to …
have been obtained mostly in non-Hodgkin lymphomas. The objective of this study was to …
Multiples Myelom–Aktuelle Standards in Diagnostik und Therapie
M Kehrer, S Koob, A Strauss, DC Wirtz… - … für Orthopädie und …, 2017 - thieme-connect.com
Hintergrund Das multiple Myelom (MM) ist als maligne hämatologische Systemerkrankung
nach Einteilung der Weltgesundheitsorganisation (WHO) dem Formenkreis der …
nach Einteilung der Weltgesundheitsorganisation (WHO) dem Formenkreis der …
[PDF][PDF] Clinical Practice Guideline
B Augustson–WA, A Kalff–VIC, F Szabo–NT… - myeloma.org.au
Multiple myeloma (MM) is a malignancy of plasma cells characterised by an abnormal
serum and/or urine immunoglobulin or free immunoglobulin light chain as a result of clonal …
serum and/or urine immunoglobulin or free immunoglobulin light chain as a result of clonal …